Search
2026
2025
2024
2023
-
Jul 20, 2026
YolTech Therapeutics Appoints Jessie Yeung as Chief Financial OfficerRead More
-
Jun 30, 2026
YolTech at Hope for Rare Science Conference 2026Read More
-
Jun 26, 2026
YolTech to Present Interim Clinical Data of YOLT-203 at the 2026 OHF International Hyperoxaluria WorkshopRead More
-
May 29, 2026
YolTech Therapeutics Raises $70 Million in Series C FinancingRead More
-
May 14, 2026
YolTech Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation to YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)Read More
